{"id":384464,"date":"2020-11-18T16:18:25","date_gmt":"2020-11-18T21:18:25","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=384464"},"modified":"2020-11-18T16:18:25","modified_gmt":"2020-11-18T21:18:25","slug":"rm-law-announces-investigation-of-urovant-sciences-ltd","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-urovant-sciences-ltd\/","title":{"rendered":"RM LAW Announces Investigation of Urovant Sciences Ltd."},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">BERWYN, Pa.<\/span>, <span class=\"xn-chron\">Nov. 18, 2020<\/span> \/PRNewswire\/ &#8212;\u00a0 <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2986569-2&amp;h=3798231889&amp;u=http%3A%2F%2Frmclasslaw.com%2Fcase%2Furov&amp;a=RM+LAW%2C+P.C.\" rel=\"nofollow noopener noreferrer\">RM LAW, P.C.<\/a>\u00a0announces an investigation on behalf of Urovant Sciences Ltd. (&#8220;Urovant&#8221; or the &#8220;Company&#8221;) (NASDAQ: UROV) regarding possible breaches of fiduciary duties and other violations of law related to Urovant&#8217;s agreement to be acquired by Sumitovant Biopharma Ltd. <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/454766\/RM_LAW_PC_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/454766\/RM_LAW_PC_Logo.jpg\" title=\"\" alt=\"\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>If you purchased shares of Urovant and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact <span class=\"xn-person\">Richard A. Maniskas, Esquire<\/span> toll-free at (844) 291-9299 or to sign up online, click <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2986569-2&amp;h=567056678&amp;u=http%3A%2F%2Frmclasslaw.com%2Fcase%2Furov&amp;a=here\" rel=\"nofollow noopener noreferrer\">here<\/a>. <\/p>\n<p>Under the terms of the agreement, Urovant&#8217;s shareholders will receive <span class=\"xn-money\">$16.25<\/span> in cash per share.\u00a0 <\/p>\n<p>For more information regarding this, please contact RM LAW, P.C. \u00a0(<span class=\"xn-person\">Richard A. Maniskas, Esquire<\/span>) toll-free at (844) 291-9299 or by email at <a target=\"_blank\" href=\"mailto:rm@maniskas.com\" rel=\"nofollow noopener noreferrer\">rm@maniskas.com<\/a>\u00a0or click <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2986569-2&amp;h=567056678&amp;u=http%3A%2F%2Frmclasslaw.com%2Fcase%2Furov&amp;a=here\" rel=\"nofollow noopener noreferrer\">here<\/a>.\u00a0\u00a0 For more information about class action cases in general or to learn more about RM LAW, P.C. please visit our website by clicking <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2986569-2&amp;h=3603698765&amp;u=http%3A%2F%2Fwww.rmclasslaw.com%2F&amp;a=here\" rel=\"nofollow noopener noreferrer\">here<\/a>.\u00a0 <\/p>\n<p>RM LAW, P.C. is a national shareholder litigation firm.\u00a0 RM LAW, P.C. is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.<\/p>\n<div>\n<table id=\"convertedTable9f19\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\" class=\"prntblns\">\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>CONTACT:\u00a0\u00a0<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2986569-2&amp;h=4255152025&amp;u=http%3A%2F%2Fwww.rmclasslaw.com%2F&amp;a=RM+LAW%2C+P.C.\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\"><br \/>\n                    <b>RM LAW, P.C.<\/b><br \/>\n                  <\/a><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\">\n              \n            <\/td>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Richard A. Maniskas, Esquire<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\">\n              \n            <\/td>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">1055 Westlakes Dr., Ste. 300<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\">\n              \n            <\/td>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Berwyn, PA 19312<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\">\n              \n            <\/td>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">484-324-6800<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\">\n              \n            <\/td>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">844-291-9299<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\">\n              \n            <\/td>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"mailto:rm@maniskas.com\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">rm@maniskas.com<\/a><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC96840&amp;sd=2020-11-18\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/rm-law-announces-investigation-of-urovant-sciences-ltd-301176419.html\">http:\/\/www.prnewswire.com\/news-releases\/rm-law-announces-investigation-of-urovant-sciences-ltd-301176419.html<\/a><\/p>\n<p>SOURCE  RM LAW, P.C.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=DC96840&amp;Transmission_Id=202011181615PR_NEWS_USPR_____DC96840&amp;DateId=20201118\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire BERWYN, Pa., Nov. 18, 2020 \/PRNewswire\/ &#8212;\u00a0 RM LAW, P.C.\u00a0announces an investigation on behalf of Urovant Sciences Ltd. (&#8220;Urovant&#8221; or the &#8220;Company&#8221;) (NASDAQ: UROV) regarding possible breaches of fiduciary duties and other violations of law related to Urovant&#8217;s agreement to be acquired by Sumitovant Biopharma Ltd. If you purchased shares of Urovant and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (844) 291-9299 or to sign up online, click here. Under the terms of the agreement, Urovant&#8217;s shareholders will receive $16.25 in cash per share.\u00a0 For more information regarding this, please contact RM &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-urovant-sciences-ltd\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;RM LAW Announces Investigation of Urovant Sciences Ltd.&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-384464","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>RM LAW Announces Investigation of Urovant Sciences Ltd. - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-urovant-sciences-ltd\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RM LAW Announces Investigation of Urovant Sciences Ltd. - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire BERWYN, Pa., Nov. 18, 2020 \/PRNewswire\/ &#8212;\u00a0 RM LAW, P.C.\u00a0announces an investigation on behalf of Urovant Sciences Ltd. (&#8220;Urovant&#8221; or the &#8220;Company&#8221;) (NASDAQ: UROV) regarding possible breaches of fiduciary duties and other violations of law related to Urovant&#8217;s agreement to be acquired by Sumitovant Biopharma Ltd. If you purchased shares of Urovant and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (844) 291-9299 or to sign up online, click here. Under the terms of the agreement, Urovant&#8217;s shareholders will receive $16.25 in cash per share.\u00a0 For more information regarding this, please contact RM &hellip; Continue reading &quot;RM LAW Announces Investigation of Urovant Sciences Ltd.&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-urovant-sciences-ltd\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-18T21:18:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/454766\/RM_LAW_PC_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rm-law-announces-investigation-of-urovant-sciences-ltd\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rm-law-announces-investigation-of-urovant-sciences-ltd\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"RM LAW Announces Investigation of Urovant Sciences Ltd.\",\"datePublished\":\"2020-11-18T21:18:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rm-law-announces-investigation-of-urovant-sciences-ltd\\\/\"},\"wordCount\":244,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rm-law-announces-investigation-of-urovant-sciences-ltd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/454766\\\/RM_LAW_PC_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rm-law-announces-investigation-of-urovant-sciences-ltd\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rm-law-announces-investigation-of-urovant-sciences-ltd\\\/\",\"name\":\"RM LAW Announces Investigation of Urovant Sciences Ltd. - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rm-law-announces-investigation-of-urovant-sciences-ltd\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rm-law-announces-investigation-of-urovant-sciences-ltd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/454766\\\/RM_LAW_PC_Logo.jpg\",\"datePublished\":\"2020-11-18T21:18:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rm-law-announces-investigation-of-urovant-sciences-ltd\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rm-law-announces-investigation-of-urovant-sciences-ltd\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rm-law-announces-investigation-of-urovant-sciences-ltd\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/454766\\\/RM_LAW_PC_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/454766\\\/RM_LAW_PC_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rm-law-announces-investigation-of-urovant-sciences-ltd\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RM LAW Announces Investigation of Urovant Sciences Ltd.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RM LAW Announces Investigation of Urovant Sciences Ltd. - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-urovant-sciences-ltd\/","og_locale":"en_US","og_type":"article","og_title":"RM LAW Announces Investigation of Urovant Sciences Ltd. - Market Newsdesk","og_description":"PR Newswire BERWYN, Pa., Nov. 18, 2020 \/PRNewswire\/ &#8212;\u00a0 RM LAW, P.C.\u00a0announces an investigation on behalf of Urovant Sciences Ltd. (&#8220;Urovant&#8221; or the &#8220;Company&#8221;) (NASDAQ: UROV) regarding possible breaches of fiduciary duties and other violations of law related to Urovant&#8217;s agreement to be acquired by Sumitovant Biopharma Ltd. If you purchased shares of Urovant and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (844) 291-9299 or to sign up online, click here. Under the terms of the agreement, Urovant&#8217;s shareholders will receive $16.25 in cash per share.\u00a0 For more information regarding this, please contact RM &hellip; Continue reading \"RM LAW Announces Investigation of Urovant Sciences Ltd.\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-urovant-sciences-ltd\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-18T21:18:25+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/454766\/RM_LAW_PC_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-urovant-sciences-ltd\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-urovant-sciences-ltd\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"RM LAW Announces Investigation of Urovant Sciences Ltd.","datePublished":"2020-11-18T21:18:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-urovant-sciences-ltd\/"},"wordCount":244,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-urovant-sciences-ltd\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/454766\/RM_LAW_PC_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-urovant-sciences-ltd\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-urovant-sciences-ltd\/","name":"RM LAW Announces Investigation of Urovant Sciences Ltd. - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-urovant-sciences-ltd\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-urovant-sciences-ltd\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/454766\/RM_LAW_PC_Logo.jpg","datePublished":"2020-11-18T21:18:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-urovant-sciences-ltd\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-urovant-sciences-ltd\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-urovant-sciences-ltd\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/454766\/RM_LAW_PC_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/454766\/RM_LAW_PC_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rm-law-announces-investigation-of-urovant-sciences-ltd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"RM LAW Announces Investigation of Urovant Sciences Ltd."}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=384464"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384464\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=384464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=384464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=384464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}